426 related articles for article (PubMed ID: 19166444)
1. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
Sreenan S; Virkamäki A; Zhang K; Hansen JB;
Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
[TBL] [Abstract][Full Text] [Related]
2. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
Yenigun M; Honka M
Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
[TBL] [Abstract][Full Text] [Related]
3. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
4. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
Pediatr Diabetes; 2011 Nov; 12(7):632-41. PubMed ID: 21418455
[TBL] [Abstract][Full Text] [Related]
5. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
Dornhorst A; Lüddeke HJ; Honka M; Ackermann RW; Meriläinen M; Gallwitz B; Sreenan S;
Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
[TBL] [Abstract][Full Text] [Related]
7. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
Oishi M; Abe N; Yokoyama H; Kuribayashi N; Tomonaga O; Matoba K; Kobayashi M;
J Int Med Res; 2012; 40(2):787-97. PubMed ID: 22613444
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
Bartley PC; Bogoev M; Larsen J; Philotheou A
Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
10. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
11. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
[TBL] [Abstract][Full Text] [Related]
14. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
15. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
16. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
Garber AJ; Clauson P; Pedersen CB; Kølendorf K
J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
[TBL] [Abstract][Full Text] [Related]
17. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
De Leeuw I; Vague P; Selam JL; Skeie S; Lang H; Draeger E; Elte JW
Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
[TBL] [Abstract][Full Text] [Related]
18. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
[TBL] [Abstract][Full Text] [Related]
19. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.
Pieber TR; Draeger E; Kristensen A; Grill V
Diabet Med; 2005 Jul; 22(7):850-7. PubMed ID: 15975098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
